The Magazine for Sleep Professionals
Saturday, September 26, 2026
Ognomy Sleep, announced the closing of a $20 million Series A financing round led by Catalyst Investors, with participation from Blue Heron Capital. The round also included new and follow-on investments from Impellent Ventures, LaunchNY, Excell and Upstate Biotech Ventures, University of Buffalo, and strategic partners who have supported the company’s […]
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]
LivaNova PLC announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with […]
